Palvella Completes NDA Submission for QTORIN Rapamycin, Eyes 2027 Launch
PVLA has more than doubled off its 52-week low of $49.806.
Summary
Palvella has completed the rolling NDA submission for QTORIN rapamycin in microcystic lymphatic malformations, a milestone that triggers FDA's 60-day filing review and potential Priority Review. The submission includes Phase 3 SELVA data showing 86% of patients rated Much/Very Much Improved at Week 24 with all six efficacy endpoints statistically significant (p<0.001) and no drug-related serious adverse events. This follows the first module submission disclosed in the Q2 8-K on August 4, and the company is now preparing for a potential commercial launch in the first half of 2027. With $250.6 million in cash as of Q2, Palvella is well-funded through the review period. The FDA's decision on Priority Review within 60 days is the next key catalyst.
At the time of this announcement, PVLA was trading at $150.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $49.81 to $161.38. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.